CBA Greater Philadelphia Chapter
Mission
CBA-GP is devoted to promoting biotechnology innovation, product incubation, and commercial transformation. We emphasize strengthening collaborations and connections between academia and industry while providing strategies and assistance for professional development.
About CBA-GP
The Chinese Biopharmaceutical Association – Greater Philadelphia (CBA-GP) is a new chapter of Chinese Biopharmaceutical Association, USA (CBA) established in 2023. The CBA-GP is an independent, non-political, non-profit professional organization. The executive team of CBA-GP consists of academic professors (from institutions such as Temple, UPenn, Drexel, Villanova, Blumberg, Lehigh, Rutgers, Weill Cornell, UTMB), entrepreneurs (founders/CEOs), and industry executives (from biopharmaceutical companies such as Johnson & Johnson, Merck, GSK, BMS).
Check out our annual jounal to know more about our events.
About CBA: CBA is one of the largest Chinese American professional associations in the US (www.cba-usa.org). Founded in 1995 in Maryland as an independent, non-political, not-for-profit professional organization. CBA has attracted over 10,000 members with more than 80% having PhD/MD degrees. We are excited to expand this established organization to the Great Philadelphia area to serve the local scholars, entrepreneurs, and biotech and pharma professionals. The CBA-GP is also an independent, non-profit and non-political organization.
Since
Members
Time to Next Event
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
NEWS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
EVENTS
Introduction to NIH Small Business Grants – Zoom Webinar – May 3, 2023
The first event notice from the CBA-GP Chinese Biopharmaceutical Association of Greater...
CBA Greater Philadelphia Chapter Opening Ceremony and Innovation Entrepreneurship Forum
The Chinese Biopharmaceutical Association, USA - Greater Philadelphia (CBA-GP) held its opening...
Membership
As a member of CBA-GP, you have the privilege of participating in CBA-GP and CBA events and activities for free or at a reduced cost.
Membership type:
Regular Member $40.00
Postdoctoral Member $20.00
Student Member $20.00
Life Time Member $400.00
Corporate Member $500.00
Please register CBA-GP membership here: https://forms.gle/MztQchRQ4C999WuR7 or scan the QR code, and make your payment here.
Executive Team
Ling Yang, PhD
Board Chairman
Assistant Professor at Temple University, interested in gene and RNA therapy. Graduated from Chinese Academy of Sciences
Qing Liang, PhD
President of CBA – GP
Medical Physicist, former Vice President in a biotech company and assistant professor at Temple university. Graduated from Tsinghua University and University of Wisconsin-Madison
Daniel Zhu, MD, PhD
President Elect of CBA – GP
- About Us
- Biotechnology Innovations
- Preclinical Drug Development
- Clinical Drug Development
- Entrepreneurship and Venture Capital
- Patent and Tech Transfer
- Workshop
- Sponsor Relationship
- Membership
- Career Development
- Marketing and Media
- Logistics
- Strategy Advisors
- Volunteers
The executive team has 11 main functions including the following. Click each tab above to see who we are.
Weidong Xiao, PhD
Vice President
Founder and CEO of Nikegen, Professor at Indiana University, interested in molecular virology, development of vectors for gene therapy, and treatment of hemophilia. Graduated from University of North Carolina-Chapel Hill
Zuyi Huang, PhD
Vice President
Associate Professor at Villanova University, interested in systems biology, drug discovery, gene and cell therapy. Graduated from Tsinghua University and Texas A&M University
Yanming Du, PhD
Vice President
Professor and Director of Medicinal Chemistry at Baruch S. Blumberg Institute (BSBI), expertise in medicinal chemistry for infectious diseases, graduated from Jilin University, Wuhan University, and University of Iowa
Ju-Tao Guo, PhD
Vice president
Thomas London Distinguished Professor; Chair, and Vice President at Baruch S. Blumberg Institute (BSBI). Graduated from Peking Union Medical College (PUMC), and Lanzhou University
Mingjing Zhou, PhD
Vice President
CEO & Co-Founder of Genemagic Biosciences, interested in neural regeneration to cure patients with CNS diseases. Graduated from Peking University
Shuibing Chen, PhD
Vice President
The Kilts Family Professor, the Director of the Diabetes Program, and Vice Chair of Innovation at the Department of Surgery, Director of the Center of Genomic Health at Weill Cornell Medicine, interested in human pluripotent stem cell-derived organoids for disease modeling and drug screening. Graduated from the Scripps Research Institute and Tsinghua University
Yaling Liu, PhD
Vice President
Professor and Director of Graduate Studies of Bioengineering at Lehigh University, interested in organ-on-chip and precision medicine. Graduated from Tsinghua University and Northwestern University.
Jinglin Fu, PhD
Vice President
Associate Professor at Rutgers University-Camden, interested in nucleic acids technology, drug delivery, bionanomaterials and biotechnology. Graduated from Zhejiang University and Arizona State University.
Weifeng Xu, PhD
Vice President
Director, leading Cell Assay Group at Preclinical Development, Regulated Bioanalytics, Merck. Weifeng has been in the field of immunogenicity for more than 10 years, with multiple patents as well as co-editor of a book in the field, supported dozens of biotherapeutics. Graduated from Chinese Academy of Science.
Jinhong Chang, MD, PhD
Vice President
Professor and Principal Investigator at Baruch S. Blumberg Institute (BSBI), interested in molecular virology, innate immunity, and antiviral drug discovery. Graduated from Peking University
Guosheng Wu, PhD
Vice President
Vice-President of Computational Drug Discovery at Pharmaron. Graduated from Northwestern University
Jun Wang, PhD
Vice President
Associate Professor and Director of Medicinal Chemistry graduate program at the Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, interested in antiviral drug discovery, drug resistance, and target validation. Graduated from Wuhan University and the University of Pennsylvania.
Richard Huang, PhD
Director
CMC program management at Alexion. Graduated from Rensselaer Polytechnic Institute
Zhongmin Alex Ma, PhD
Vice President
Founder and CEO of Revivallon, former professor at Mount Sinai School of Medicine, interested in pancreatic β-cell regeneration and drug development to treat diabetes. Graduated from Fudan University and St. Louis University.
Yi Zhu, MD, MBA
Vice President
Vice President of Global Clinical Development and Clinical Operations at Ionova Life Sciences. 25+ years clinical research experiences, R&D management, and commercial management experiences in academic institutes; pharmaceutical Industry, Biotech Industry as well as in CRO business. Graduated from Chongqing University of Medical Sciences, University of Pennsylvania, and University of Delaware
Xiaoqing Zhang, MD, PhD, MBA, PhD
Vice President
Sr. Clinical Trial Physician, Global Drug Development, Bristol Myers Squibb. Interested in oncology clinical development strategy and planning, study design from FIH to registrational trials, due diligence for BD projects, etc. Graduated from Shanghai Jiaotong University and Upenn Wharton School of Business.
Daniel Zhu, MD, PhD
Vice President
Senior Clinical Trial Physician at BMS, worked as clinical lead and pharmacovigilance lead in both big pharma and middle/small size pharma. Graduated from Second Military Medical University and University of Maryland
Bonnie Wu, PhD
Vice President
Associate Scientific Director at Janssen Research & Development. Graduated from Peking University and University of Rochester.
Zak Huang, MD
Vice President
Retired regulatory affairs executive, with extensive product development experience for pharmaceuticals, biologics, and medical devices in a setting of either a big Pharma or biotech, plus organizational leadership expertise in building and leading a regulatory team as well as an R&D organization.
Qi Xia, PhD
Vice President & Chief Financial Officer
Experienced lead biostatistician in all stages of oncology clinical trials including solid tumor and hematological malignancy. Graduated from Temple University and University of Southern California.
Wenhui Hu, MD, PhD
Vice President
Professor at Temple University, interested in targeted gene therapy, CRISPR/Cas genome editing, HIV/NeuroHIV cure. Graduated from Peking Union Medical College (PUMC)
Holly Meng, MBA
Vice President
President and CEO of the American Center for Asian Students, and an Advisory Board member of Campus Philly. Graduated from Saint Joseph University
Haitao Hu, PhD
Vice President
Associate Professor at the University of Texas Medical Branch (UTMB), interested in mechanisms of host-virus interactions, antiviral immunity, and development of vaccines and therapeutics. Graduated from the University of Pennsylvania
Jiawei Tang
Vice President
Vice President of Business Strategy at H.L.H, big passionate on health equity, gender equity and environment protection. Graduated from Shenyang Pharmaceutical University
Zijie Feng, PhD
Vice President
Co-founder & Director of technology development in a Biotech company, SidoCel, interested in immunotherapy including CAR T cell therapy and ADC drug to treat solid tumors and leukemia. Graduated from Xiamen University
Xiaoxiao Lu, MD, PhD
Vice President
Director of Real World Value & Evidence at Janssen oncology. Graduated from Tongji Medical College and University of Maryland
Jian Huang, MD, PhD
Vice President
Associate Professor at Coriell Institute for Medical Research, interest in hematopoietic stem cell signal transduction control, fate decision regulation, leukemia drug resistance. Graduated from Peking University Health Science Center and State University of New York Downstate medical center.
Hanghang Zhang, MD, PhD
Vice President
Founder and CEO of NexStage Bi
o, interested in epigenetic therapy, cell and gene therapy, and medical device development. MD, PhD from Lewis Katz School of Medicine at Temple University.
George Li, PhD
Vice President
Founder and CEO of CombiPhos Catalysts, Inc., interested in discovery of Deuterium Drugs, and development of “tailor-made” life-saving deuterium drugs for cancer patients who have “no drug available”. Graduated from Northwestern University.
Feng Roger Luo
Vice President
Chief Development Officer, Head of Clinical and Preclinical Development at Overland Pharmaceuticals. Graduated from North Carolina at Chapel Hill.
Deping Chai, J.D., M.A
Vice President
Partner at Morgan Lewis, prosecuting patent applications in the life sciences, chemistry, and materials science industries. Graduated from Temple University and Peking University.
Xiao Wang, PhD
Vice President
Research Assistant Professor at the University of Pennsylvania, interested in identifying genetic factors related to diseases, and using novel genome-editing tools to develop new therapies. Graduated from Chinese Academy of Sciences.
Xiaodan Ji, PhD
Vice President
Principal Investigator at GSK. Expertise in CHO cell line development, upstream process development and regulatory filing. Graduated from Chinese Academy of Sciences
Kevin He, MBA
Vice President
Director of Business Operations at uBriGene Biosciences, over 15 years of sales and marketing experience in the financial, industry gas, and biotech industries. Graduated from Penn State University
Julia Su, PhD
Vice President
Associate Director of Business Development at WuXi Biologics, focusing on protein/antibody drug discoveries. Graduated from Nanjing University and Louisiana State University
Yichen Zhang, Ph.D, MPH
Director
Senior Manager of Global Health Economics and Outcomes Research at BioMarin Pharmaceutical Inc.. Interested in HEOR, Health Policy research in oncology, rare disease, and chronic disease. Graduated from Tulane University.
Mingyue (Vivian) Li, PhD
Senior Director
Investigator at GSK, interested in research and development of novel therapies. Graduated from the Chinese University of Hong Kong
Xing Liu, Ph.D
Director
Principal Scientist II – R&D at SEED therapeutics. Expertise in molecular glue drug discoveries. Graduated from Chinese Academy of Sciences
Selina Chen, PhD
Director
Scientist at WuxiAppTec, Philadelphia. Expertise in molecular analytical assays. Graduated from University of Science and Technology of China
Long Geng, MS
Director
Lab Manager at Frontage Lab. Expertise in small/ large molecule bioanalysis. Graduated from New Jersey Institute of Technology (NJIT)
Qingchun Lu, MD
Director
Postdoctoral Fellow at Temple University, interested in RNA therapy, cholesterol metabolism, and cancer. Graduated from Sichuan University
Jingyu Luan, PhD, RAC (Senior Director of Global Regulatory Affairs, AstraZeneca, CBA President Elect)
Song Wu, PhD (Head of Translational Medicine, Hansoh Bio/Hansoh Pharm, CBA President)
Hang Lu, MD (Founder and CEO of NextTranslate Biopharmaceutical, Past CBA President)
Dong Shen, PhD (Founder and CEO of RNAimmune, Immediate Past CBA President)
Dajun Yang, PhD (Chairman, CEO, Co-Founder, Ascentage Pharma, Former CBA President)
Patrick Lu, PhD (Founder, Chairman and CEO, Sirnaomics, Inc. Co-founder of CBA, Former CBA President (2nd).)
Frank Li, PhD (Founder and Senior Consultant, BLA Regulatory, Former CBA President)
Yang Liu, PhD (Founder, Chairman, CEO, and CSO, OncoC4)
Special thanks to our volunteers:
Lisa Tang
Ting Yang
Sponsors and Partners
The recruitment of sponsors for CBA-GP’s 2023-2024 annual partnership program is officially underway. We cordially invite colleagues and corporate entities from the biopharmaceutical and biotechnology industry to join us. This year’s sponsorship opportunities are divided into four tiers: Diamond, Platinum, Gold, and Silver, each offering corresponding package benefits. In addition to on-site exhibition opportunities at the annual conference, CBA-GP’s partners will also receive promotional exposure throughout the 2023-2024 CBA-GP events. Click here to sponsor or parter with us. For further details, please contact Kevin He, Vice President in charge of sponsors at kevinhe06@gmail.com. CBA-GP looks forward to mutual support and collaboration with both new and existing partners.
Diamond Sponsors
Platinum Sponsors
Gold Sponsors
Silver Sponsors
Corporate Member
